On August 8, 2024, the Board of Directors of TaiMed Biologics approved the company's financial report for the second quarter of 2024. The accumulated operating revenue for the first half of the year was NT$325,888 thousand, representing an increase of approximately 85% compared to NT$176,010 thousand for the same period last year. The gross profit margins for both the first and second quarters remained steady at 39%. The accumulated net loss for the first half of the year was NT$43,571 thousand, a reduction of approximately 66% compared to the net loss of NT$128,646 thousand for the same period last year. The net loss per share was NT$0.17, significantly decreasing from NT$0.51 per share last year.

The company successfully completed a cash capital increase of NT$1.64 billion in the first half of the year, raising the net asset value per share to NT$15.34 as of June 30, 2024, compared to NT$10.14 as of December 31, 2023, thereby significantly enhancing the financial structure. The operating cash flow for the first two quarters of 2024 has been positive, with a net cash inflow of NT$76,736 thousand for the first half of the year, compared to a net cash outflow of NT$68,745 thousand for the same period last year. This marks the best financial performance in the company's history.